Form 4 for LLY Lilly (Eli)
Accepted 2025-02-12 00:00:00 ET · period of report 2025-02-10 · accession 0000059478-25-000057 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-12 | 2025-02-10 | LLY | Van Naarden Jacob | EVP, Pres, Lilly Oncology | A - Grant | $868.88 | +6,104 | 19.6K | +45% | +$5.30M |
| D | 2025-02-12 | 2025-02-10 | LLY | Van Naarden Jacob | EVP, Pres, Lilly Oncology | A - Grant | $0.00 | +4,108 | 4,108 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-10 | A | A | 6,103.82 | $868.88 | 19,561.99 | D | — | — | |
| 2 | Derivative | Restricted Stock Unit | 2025-02-10 | A | A | 4,108 | $0.00 | 4,108 | D | — · 2026-02-01 to 2026-02-01 | 4,108 Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |